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Functional Effects of Polymorphisms in the Human
Gene Encoding 11-Hydroxysteroid Dehydrogenase
Type 1 (11-HSD1): A Sequence Variant at the
Translation Start of 11-HSD1 Alters Enzyme Levels
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Rachel S. Dakin, Uberto Pagotto, Renato Pasquali, Brian R. Walker,
and Karen E. Chapman
Centre for Cardiovascular Science (E.L.V.M., V.K., N.N., R.S.D., B.R.W., K.E.C.), Queen’s Medical
Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom; and Division of
Endocrinology (E.L.V.M., A.G., U.P., R.P.), Department of Clinical Medicine, S. Orsola-Malpighi Hospital,
University of Bologna, 40138 Bologna, Italy
Regeneration of active glucocorticoids within liver and adipose tissue by the enzyme 11-hydrox-
ysteroid dehydrogenase type 1 (11-HSD1) may be of pathophysiological importance in obesity
andmetabolic syndromeand is a therapeutic target in type2diabetes. Polymorphisms inHSD11B1,
the gene encoding 11-HSD1, have been associatedwithmetabolic phenotype in humans, includ-
ing type 2 diabetes and hypertension. Here, we have tested the functional consequences of two
single nucleotide polymorphisms located in contexts that potentially affect tissue levels of 11-
HSD1. We report no effect of allelic variation at rs846910, a polymorphism within the 5-flanking
region of the gene on HSD11B1 promoter activity in vitro. However, compared with the common
G allele, the A allele of rs13306421, a polymorphism located two nucleotides 5 to the translation
initiation site, gave higher 11-HSD1 expression and activity in vitro and was translated at higher
levels in in vitro translation reactions, possibly associated with a lower frequency of “leaky scan-
ning.” These data suggest that this polymorphism may have direct functional consequences on
levels of 11-HSD1 enzyme activity in vivo. However, the rs13306421 A sequence variant originally
reported in other ethnic groups may be of low prevalence because it was not detected in a pop-
ulation of 600 European Caucasian women. (Endocrinology 151: 195–202, 2010)
The microsomal enzyme 11-hydroxysteroid dehydro-genase type 1 (11-HSD1) generates active glucocor-
ticoids (cortisol, corticosterone) from intrinsically inert
11-keto substrates (cortisone,11-dehydrocorticosterone),
thus amplifyingglucocorticoidaction in cells and tissues in
which it is expressed (1, 2). Recent evidence has indicated
a pathogenic role for 11-HSD1 in metabolic disease. A
number of studies have demonstrated a strong association
in humans between the level of 11-HSD1 expression in
adipose tissue and body mass index (reviewed in Refs. 2
and 3). Moreover, 11-HSD1 expression in omental ad-
ipose tissue correlates with fat cell size independently of
obesity (4). A causative role is suggested by the phenotype
of transgenic mice which overexpress 11-HSD1 in adi-
pose tissue (5). These mice develop all the major features
of metabolic syndrome, including central obesity, insulin
resistance, dyslipidaemia, and hypertension (5, 6). Mice
overexpressing 11-HSD1 in liver also show insulin re-
sistance andhypertensionbut remain lean (7).Conversely,
11-HSD1 inhibition increases hepatic insulin sensitivity
in humans (8), and its deficiency or inhibition ameliorates
the metabolic consequences of obesity, increasing insulin
sensitivity and reducing blood glucose levels in obese or
diabetic mice (9–13).
Sequence variation inHSD11B1, the human gene encod-
ing11-HSD1, has been linkedwith cardiovascular risk fac-
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tors associatedwithobesity inadults, althoughnotwithobe-
sityperse (14).HSD11B1 is transcribedfromtwopromoters
(Fig. 1), with the P2 promoter predominating in metaboli-
cally active tissues,where it is potently regulated by the tran-
scription factor CCAAT/enhancer-binding protein (C/
EBP) (15). Polymorphisms in the P2 promoter region
(rs846910) and an intronic enhancer (rs12086634) are
associated with type 2 diabetes and/or hypertension in
three different populations (16–18), and the G allele of
rs12086634, associated with lower 11-HSD1 transcrip-
tional activity in vitro (19),maybeprotective against obesity
among patients with polycystic ovary syndrome (PCOS)
(20).Moreover, the combinationof less commonallelic vari-
ants at rs846910 and rs12086634 is associated with higher
levels of 11-HSD1mRNA and activity in adipose tissue in
Southern European Caucasian women with and without
PCOS (Gambineri, A., F. Tomassoni, A. Munarini, R. H.
Stimson, U. Pagotto, R.Mioni, K. E. Chapman, R. Andrew,
R. Pasquali, and B. R. Walker, submitted for publication).
However, with the exception of rs12086634, the functional
relevance of these and other nonexonic polymorphisms has
not been reported.
Here, we have investigated the effect of two polymor-
phisms upon 11-HSD1 transcription and translation:
rs846910 located 2937 nucleotides 5 to the transcription
start of the HSD11B1 P2 promoter, and rs13306421, a
polymorphism situated at2 with respect to the transla-
tion start site (Fig. 1). The translation start of HSD11B1
lies in a suboptimal context, with deviation from the con-
sensus ribosome binding site (21) (Fig. 1B) and with ad-
ditional AUG codons located close downstream. When a
pyrimidine occupies position3 (as it does inHSD11B1),
translation becomes sensitive to changes at other posi-
tions, including2 (21).Moreover, even small departures
from the consensus ribosome binding site allow nearby
AUG codons to be reached by leaky scanning (22). Ac-
cordingly, we have tested the effect of the rs13306421
polymorphism on activity of 11-HSD1 and its transla-
tion in vitro.
Materials and Methods
Plasmids
To test the effect of rs846910, the 5-flanking region (4643 to
88) of HSD11B1 was amplified from BAC DNA (RP1-28O10,
encompassing the HSD11B1 gene, obtained from the Sanger
Institute, Hinxton, UK) using primers 5-TCCCTAGCAGAGGT-
TCTCCATGAGG-3 and 5-AGCTGGCCTGAAGACTCCTG-
TAGG-3 and Accuprime Pfx (Invitrogen, Paisley, UK), a high-
fidelity thermostable polymerase. Sequencing confirmed the
presence of the more common G allele in the cloned product. The
PCR product was subcloned into pSV0L (23), and the A allele
of rs846910 introduced by site-directed mutagenesis using a
QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla,
CA) according to the manufacturer’s instructions, creating plas-
mids pHSD11B1(2937A)-Luc and pHSD11B1(2937G)-Luc,
differing only at the single nucleotide polymorphism (SNP) at
2397. Plasmids to test the effect of rs13306421, the translation
start site SNP were constructed from pBS-SK-h11-HSD1, en-
coding human11-HSD1 (24), a gift fromPerrinWhite. pBS-SK-
h11-HSD1wasfirstdigestedwithEco0109I toremoveafragment
of lacDNA originating from the  vector used to clone the cDNA.
Sequencingconfirmedthepresenceof theGalleleat2withrespect
to the translation start site; this plasmid was named pBS-h11-
HSD1(G). Site-directedmutagenesis to change theGallele toAwas
carriedout (asabove) tocreatepBS-h11-HSD1(A).Thetwoalleles
of 11-HSD1 were subcloned into pcDNA3.1() (Invitrogen) us-
ing standard techniques to generate pCMV-h11-HSD1(G) and
pCMV-h11-HSD1(A). To test whether the translation start poly-
morphism could affect translation of a heterologous protein, we
replacedthecodingsequenceof11-HSD1with luciferase, creating
pCMV-(G)Luc and pCMV-(A)Luc, as follows: The 11-HSD1
leader sequencewith either theGor theAalleleof SNPrs13306421
was amplified by PCR from pCMV-h11-HSD1(G) and pCMV-
h11-HSD1(A) using a T7 (forward) primer and a reverse primer;
either 5-ATGGCGCCGGGCCTTTCTTTATGTTTTTGGCGT-
CTTCCATCCGACAGGGAG-3 (G allele; the translation start
and 2 nucleotide are underlined) or 5-ATGGCGCCGGGC-
CTTTCTTTATGTTTTTGGCGTCTTCCATCTGACAGGGA-
G-3 (A allele). The product included an NheI restriction enzyme
site from the polylinker in pCMV-h11-HSD1(G)/(A) and a KasI
site in the reverse primer. pCMV-(G)Luc and pCMV-(A)Luc were
thenassembled inpcDNA3.1() fromanNheI-KasI fragment from
thePCRproductandaKasI-SpeI fragmentencodingluciferasefrom
pGL3-basic (Promega, Southampton, UK). To create the N162Q
glycosylationmutant, site-directedmutagenesiswasused to change
asparagine 162 of 11-HSD1 to glutamine, as described above. All
constructs were verified by sequencing.
Cell culture and transfection
The effect of rs846910 on HSD11B1 promoter activity was
tested in A549 cells, which express the endogenous HSD11B1
gene (25). A549 cells were maintained and transfected as de-
FIG. 1. Locations of relevant SNPs: rs846910 at 2937 with respect to
the P2 promoter and rs13306421, close to the translation start of the
human HSD11B1 gene. A, Schematic representation of the 5 end of the
HSD11B1 gene. Exons 1A and 1B (and the associated P1 and P2
promoters, respectively) (15) are indicated, as is exon 2, containing the
translation start of 11-HSD1. The position of SNP rs846910 is indicated
by a section sign, and SNP rs13306421 is indicated by an asterisk. B, SNP
rs13306421 is located at2 (numbering with respect to the AUG
translation start codon at1), within the ribosome binding site of 11-
HSD1 mRNA. The ribosome binding site of HSD11B1 is a poor match to
the consensus sequence (21). When a pyrimidine replaces the preferred
purine at position3, translation becomes more sensitive to changes at
other positions, including2 (21).
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scribed (25). Briefly, 1.5  105 cells per well of a six-well plate
were transfected using lipofectamine 2000 (Invitrogen)with 250
ng of pHSD11B1(2937A)-Luc or pHSD11B1(2937G)-Luc
and 250ng pRSV-LacZ (encoding -galactosidase, as internal
control). Where appropriate, 50 ng of pMSV-C/EBP (gift from
S. McKnight; University of Texas Southwestern Medical
Center, Dallas, TX) was added. Forty-eight hours after trans-
fection, cells were lysed and luciferase and -galactosidase ac-
tivity measured as previously described (15). Transfections were
carried out in triplicate with at least two independent preparations
of each plasmid and the experiment was repeated seven times.
The effect of rs13306421 on enzyme activity of 11-HSD1 in
mammalian cells was tested in Chinese hamster ovary (CHO)
cells, which do not express endogenous 11-HSD1 activity (26,
27). CHO cells were maintained in DMEM supplemented with
10% fetal bovine serum, 100 IU/ml penicillin and 100 g/ml
streptomycin. Twenty-four hours before transfection, cells were
seeded at 1.5 105 cells/well in a six-well plate and transfected
with 500 ng of DNA using lipofectamine 2000 (Invitrogen), ac-
cording to the manufacturer’s instructions. For assay of 11-
HSD1 activity, cells were transfected with 250 ng of H6PD ex-
pression plasmid (27) and 250 ng of pCMV-h11-HSD1(G) or
pCMV-h11-HSD1(A). Controls contained pcDNA3.1()
(“empty vector”) instead of the H6PD plasmid, the pCMV-
h11-HSD1 plasmid, or both. 11-HSD1 reductase activitywas
measured by incubating intact cells with 200 nM cortisone con-
taining 5 nM [3H]-cortisone tracer for 16–24 h (preliminary ex-
periments established that conversion was linear up to at least
24 h and the time point used for each assay gave 20–40% con-
version of added substrate). After incubation, steroids were ex-
tracted with ethyl acetate, separated by thin-layer chromatog-
raphyusing amobile phaseof chloroformandethanol (92:8) and
quantitated using a phosphorimager (Fuji FLA-2000; Raytek
Scientific Ltd., Sheffield, UK). For assay of luciferase activity,
cells were transfected with 250 ng of pRSV-LacZ (to monitor
transfection efficiency) together with 250 ng of either pCMV-
(G)Luc or pCMV-(A)Luc. Forty-eight hours after transfection,
cells were lysed and luciferase and -galactosidase activity mea-
suredasabove.All transfectionswere carriedout in triplicate and
for each plasmid (A or G allele), at least three independent plas-
mid preparations were also used. Transfections were repeated
four to six times. Datawere normalized between experiments by
arbitrarily setting the mean value of the G allele to 100%.
Immunoblotting was carried out on CHO cells transfected as
above, but with 5 105 cells/well seeded in a six-well plate and
1g of pCMV-h11-HSD1(G) or pCMV-h11-HSD1(A)DNA
(three independent preparations of each plasmid). Cells were
harvested 48 h after transfection, lysed in Laemmli buffer, and
proteins (50g) separated by electrophoresis on a discontinuous
15% sodium dodecyl sulfate (SDS)-polyacrylamide resolving
gel. Proteins were transferred to Hybond nitrocellulose mem-
brane (GE Healthcare Life Sciences, Little Chalfont, UK) at 200
mA for 2 h.Membranes were blocked with 5%milk block (Bio-
Rad,HemelHempstead, UK) in Tris-buffered salinewith Tween
20 [0.015MTris, 0.15MNaCl, 0.1%Tween 20 (pH7.4)] for 1 h
at room temperature followed by overnight incubation at 4 C
with 1:1,000 dilution of sheep antihuman 11-HSD1 antibody
(The Binding Site Ltd., Birmingham, UK). Membranes were
washed in Tris-buffered saline with Tween 20, then incubated
with Alexa Fluor 680-labeled donkey antisheep antibody (In-
vitrogen) used at 1:10,000 dilution. Immunolabeling was de-
tected and quantified using anOdyssey infrared imager andOd-
yssey software (LI-COR Biosciences UK, Cambridge, UK).
In vitro translation
The mRNA encoding either the A or the G allele of
rs13306421 was transcribed and translated in vitro from pBS-
h11-HSD1(G)/(A) or pCMV-h11-HSD1(G)/(A) using the
TNTT7QuickCoupledTranscription/Translation System (Pro-
mega), according to the manufacturer’s instructions. Three in-
dependent plasmid preps for each allele were tested. Reactions
(50 l) contained 1 g template DNA, 20 Ci 35S-methionine
(37.0 TBq/mmol; PerkinElmer, Beaconsfield, UK), 1 l T7 TNT
PCR enhancer (supplied with the kit), and 40 l TNT Quick
Master Mix (supplied with the kit). Positive controls contained
1 g of a plasmid encoding luciferase (supplied with the kit);
negative controls omitted DNA template. Reactions to investi-
gate glycosylated 11-HSD1 isoforms were carried out using
pCMV-h11-HSD1(A) or the N162Q mutant of 11-HSD1 as
template, with or without inclusion of 4 l canine pancreatic
microsomes (Promega). Proteinase K sensitivity was tested by
incubating aliquots of the in vitro translation reactions with 0.2
mg/ml proteinase K on ice for 30min, in the presence or absence
of 0.5% Triton X-100. To inactivate proteinase K, 1 mM phe-
nylmethylsulfonylfluoride was added, followed by heating at
100 C, 5 min in SDS loading buffer [50 mM Tris-HCl (pH 6.8),
100 mM dithiothreitol, 2% SDS, 0.1% Bromophenol blue, 10%
glycerol. Proteins were separated by SDS-PAGE in either 15 or
10% discontinuous polyacrylamide gels. Gels were fixed for 30
min in 50%methanol, 10%glacial acetic acid followed by 5min
in 10% glycerol, then dried and exposed to autoradiographic
film or to a phosphorimager screen. Quantification was carried
out using a phosphoimager (Fuji BAS FLA-2000; Raytek Scien-
tific Ltd.) and Aida 3.44 software (Raytek Scientific Ltd.).
Genotyping of SNP rs13306421 within a
population of southern European women with
and without PCOS
Three hundred unmedicated Caucasian women with PCOS,
aged 18–45 yr, and 300 Caucasian controls recruited from the
general population inNorthern Italy and comparable for age and
body weight were genotyped for rs13306421. PCOS was diag-
nosed according to the Rotterdam consensus conference criteria
(28). Controls had no signs of hyperandrogenism and regular
ovulatory menstrual cycles (29).
Blood samples for DNA extraction were collected in EDTA
and stored at 4 C. DNA was extracted using a QIAamp DNA
Blood Kit (QIAGEN Inc., Valencia, CA). Genotyping of
rs13306421 was undertaken by single nucleotide primer exten-
sion and denaturing HPLC, adapted from (30).HSD11B1 gene
fragments were amplified by PCR for 35 cycles, each consisting
of 30 s at 95 C, 30 s at 65 C, and 20 s at 72 C. Primers for
rs13306421 were 5-GCTGCCTGCTTAGGAGGTTGTAG-3
(forward) and 5-AACACATCTTGGTCCTCAGGAACAC-3
(reverse). Reactions (10 l) contained 25 pmol each primer, 40
ng of genomic DNA, 200 M dNTPs, 2 mM MgCl2, and 0.08 U
AmpliTaq Gold (Applied Biosystems, Warrington, UK) in the
buffer provided by the manufacturer. PCR products were incu-
bated for 60minat 37Cwith2l of Exo-SAP-IT (GEHealthcare
Europe GmbH, Milan, Italy) to hydrolyze unincorporated nu-
cleotides and degrade excess primers; the reaction was termi-
nated by incubation at 80 C for 15 min. Primer extension reac-
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tions were carried out in a 25 l reaction containing the purified
PCR products, 50 M of the appropriate ddNTPs (ddATP,
ddGTP, ddCTP), 200 pmol primer (5-TTTTTTTTTTTTTTT-
TGGAGTCTTCAGGCCAGCTCCCTGTC-3), and 1.25 U
Thermo Sequenase (GEHealthcare EuropeGmbH) in the buffer
provided by the manufacturer. Single nucleotide primer exten-
sion reactions were performed in a thermal cycler with 35 cycles
each consisting of 30 sec at 94 C, 15 sec at 55 C, and 60 sec at
60 C, followed by 2 sec at 15 C. Primer extension products (10
l) were loaded on SaraSep DNASep column (Transgenomic,
Glasgow, UK) at 80 C and separated by denaturing HPLC on a
WAVE System (Transgenomic) using a linear acetonitrile gradi-
ent [over 7min from20–37%acetonitrile in 0.1M triethylamine
acetate buffer (pH7)] at a constant flow rate of 0.9ml/min. Data
were acquired using a UV-detector at 260 nm.
Results
SNP rs846910, located 2937 nucleotides 5 to the
translation start of HSD11B1, does not influence
HSD11B1 promoter activity
A549 (human lung epithelial) cells in which the endog-
enousHSD11B1 promoter is active (15) were used to test
the effect of allelic variation at2937. Luciferase reporter
plasmids encoding4643 to88 ofHSD11B1, differing
only by A/G at2937, showed similar promoter activity
in A549 cells (Fig. 2A). Moreover, cotransfection of
C/EBP, a transcription factor important for expressionof
11-HSD1 in some tissues (15) but absent fromA549 cells
(25), did not differentially regulate the A and G alleles of
rs846910 (Fig. 2B), although it did markedly increase
HSD11B1 promoter activity (fold induction with
C/EBP, mean SEM: A allele, 8.1 1.0 vs.Gallele, 8.9
1.8; P  0.7, n  7 experiments, each with more than or
equal to six replicates), consistentwith previous data (15).
The A allele of SNP rs13306421 is associated with
higher 11-HSD1 activity and confers higher
expression upon a heterologous protein
Expression plasmids encoding 11-HSD1 cDNA, dif-
fering only by A/G at 2 with respect to the translation
start site, were each cotransfected into CHO cells (which
lack endogenous 11-HSD1 activity) (26, 27) together
with an expression plasmid encoding H6PD, required for
reductase activity of 11-HSD1 (27). Empty vector or
H6PD alone gave no 11-HSD1 reductase activity in
transfected cells (data not shown). 11-HSD1 reductase
activity was higher when encoded by the A allele than the
G allele (Fig. 3A), suggesting that the leader sequence of
HSD11B1, including the Kozak sequence, determines the
translation efficiency of 11-HSD1. Consistent with this,
immunoblotting of transfected cells showed more 11-
HSD1 protein expressed from the A allele compared with
the G allele (Fig. 3, B and C). To test whether translation
of a heterologous protein was affected by the polymor-
phism, the leader sequence of 11-HSD1, including the
translation start, was used to drive luciferase expression.
Higher luciferase activity was produced from the A allele
than the G allele (Fig. 3D).
The A allele of SNP rs13306421 directs more
efficient translation of full-length 11-HSD1
in vitro
To determine whether the A allele confers higher en-
zyme activity through increased translation, mRNA en-
coding either theAallele or theGallele of rs13306421was
transcribed and translated in vitro. Four products were
obtained with both the A and the G allele, with the largest
and most abundant migrating with a relative molecular
size of approximately 29 kDa (Fig. 4, see also Fig. 5),
smaller than the predicted Mr of 32.4 kDa, but corre-
sponding to the size previously observed for in vitro-trans-
lated human 11-HSD1 (31). This suggested that trun-
cated 11-HSD1 was synthesized in addition to the full
length, giving rise to the smaller products. Addition of
unlabeled methionine together with 35S-labeled methio-
nine had no effect on the pattern of labeled products (data
not shown), indicating that they were not due to C-termi-
nal truncation because of limiting amounts of methionine
in the reactions. TheN terminus of 11-HSD1 determines
the location and orientation of 11-HSD1 in the endo-
plasmic reticulum (31), and N-terminally truncated pro-
teins would not be predicted to translocate into micro-
somes. To test this, in vitro transcription-translation was
carried out in the presence ofmicrosomes,which results in
glycosylation of 29-kDa human 11-HSD1 at three sites,
N123, N162, and N207 (31). Addition of microsomes
resulted in the appearance of three products of approxi-
FIG. 2. Allelic variation at rs846910 does not affect HSD11B1 P2
promoter activity. Panels A and B, Site-directed mutagenesis was
used to change G at 2937 (with respect to the transcription start
site of the P2 promoter, 1) to A, generating reporter plasmids
pHSD11B1(2937G)-Luc and pHSD11B1(2937A)-Luc. After
transfection into A549 cells, there was no difference in luciferase
activity directed by pHSD11B1(2937G)-Luc encoding the G allele
(black bars) and pHSD11B1(2937A)-Luc, encoding the A allele (white
bars), either in the absence (Panel A) or in the presence (Panel B) of
C/EBP. Data are expressed relative to the more common G allele,
arbitrarily set to 100% for each experiment and are means  SEM from
seven independent transfections, each carried out in triplicate and with
more than or equal to two independent plasmid preps of either the A
allele or the G allele. Significance was tested with unpaired Student’s t test.
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mately 31, 33, and 35 kDa (Fig. 4B, lanes 1 and 2), con-
sistent with previous reports of glycosylated products of
31, 33, and 35 kDa (31, 32). Moreover, when a mutant
11-HSD1 in which one of the three glycosylation sites
was mutated to glutamine (N162Q) was translated in
vitro, only two additional products were produced in the
presence of microsomes (Fig. 4B), consistent with the ef-
fect of the mutation in transfected cells (Fig. 3B, lane 1).
Themutation had no effect on the products in the absence
ofmicrosomes.Whereas the31-, 33-, and35-kDaproteins
were protected from proteinase K digestion, the 29-kDa
and smaller products were fully digested by proteinase K
(Fig. 4C, lanes 3 and 4), supporting their exclusion from
microsomes. Addition of TritonX-100 to solubilizemem-
branes rendered all the 11-HSD1 products susceptible to
proteinase K digestion (Fig. 4C, lanes 5 and 6). Quantifi-
cation of in vitro transcription-translation products from
three independentplasmidprepsof eachof theGallele and
Aallele of rs13306421 showeda significant increase in the
amount of full-length 11-HSD1 produced from the A
allele, with a concomitant decrease in the amount of the
largest truncated product (Fig. 5). Overall, the ratio of
full-length 11-HSD1 to total truncated 11-HSD1
(amount of full length/the sumof the three truncatedprod-
FIG. 3. The A allele of SNP rs13306421 is associated with higher
enzyme activity. Panel A, Site-directed mutagenesis was used to
change G at 2 of 11-HSD1 (with respect to the ATG translation
start) to A. 11-Reductase activity was measured by conversion of 200
nM [3H]-cortisone to cortisol following cotransfection of CHO cells with
expression plasmids encoding H6PD and either the G (black bar) or A
allele (white bar) of 11-HSD1. 11-HSD1 activity was normalized
between experiments by arbitrarily setting the mean conversion of
the G allele plasmids to 100% for each experiment. Panel B,
Representative Western blot analysis showing levels of 11-HSD1
protein encoded by three independent preparations of pCMV-h11-
HSD1(G) (lanes 2–4), pCMV-h11-HSD1(A) (lanes 5–7), 11-HSD1
N162Q (lane 1; a mutation at one of the glycosylation sites of human
11-HSD1), or pcDNA3.1 vector (V, lane 8). Fifty micrograms of G
protein were loaded per lane. The membrane was incubated with
sheep antihuman 11-HSD1 antibody. A cross-reacting band of
approximately 58 kDa, present in untransfected cells, was used as a
convenient loading control. Panel C, Quantification of immunoblot
shown in panel B. Levels of 11-HSD1 are expressed relative to the
loading control, with the G allele arbitrarily set to 100%. Data are
means  SEM from three independent transfections, with three
independent plasmid preps of either the A allele or the G allele.
Significance was tested with unpaired Student’s t test; ***, P  0.001.
Panel D, The A allele directs higher expression of a heterologous
protein, luciferase. The leader sequence of luciferase (to the ATG
translation start site) was replaced with the 11-HSD1 leader
sequence, either the A or G allele. Luciferase activity was measured in
transfected CHO cells. To normalize between experiments, the mean
luciferase activity of the G allele plasmid was arbitrarily set to 100% for
each experiment. Data are means  SEM from four to six independent
transfections, each carried out in triplicate and with three independent
plasmid preps of either the A allele or the G allele. Significance was
tested with unpaired Student’s t test; **, P  0.01; ***, P  0.001.
FIG. 4. The A allele of rs13306421 produces more full-length 11-
HSD1 in coupled in vitro transcription-translation reactions.
Panel A, Representative autoradiograph showing 35S-labeled products of
in vitro transcription-translation of 11-HSD1. Reactions contained 1
g of plasmid encoding the G allele (lane 1) or the A allele (lane 2) of
rs13306421, vector (negative control, indicated by a minus sign above
the lane) or luciferase (positive control, indicated by a plus sign above
the lane). An arrowhead indicates full-length 11-HSD1 migrating at
approximately 29 kDa (relative to molecular weight markers, indicated
at the right of the gel), and arrows indicate the three truncated
products obtained from the 11-HSD1 plasmids. Luciferase (Mr, 61
kDa) is indicated (Luc). Panel B, Representative autoradiograph
showing 35S-labeled products of in vitro translation reactions carried
out with plasmids encoding 11-HSD1 (lanes 1 and 2; A allele of
rs13306421) or 11-HSD1 with a mutation in one of the glyosylation
sites, N162Q (lanes 3 and 4) in the absence (lanes 1 and 3) or the
presence (lanes 2 and 4) of microsomes. An arrowhead indicates full-
length 11-HSD1, and arrows indicate the three truncated products
obtained from the 11-HSD1 plasmids. Open arrowheads indicate the
positions of glycosylated 11-HSD1. An asterisk indicates a nonspecific
band. Panel C, Representative autoradiograph showing 35S-labeled
products of in vitro transcription-translation of 11-HSD1 carried out
in the presence or absence of microsomes, Triton X-100 and proteinase
K (PK) (indicated above the lanes). Unglycosylated 11-HSD1 was
susceptible to PK digestion, whereas the glycosylated products were
protected (lanes 3 and 4). Addition of Triton X-100 to solubilize
microsomal membranes rendered all products susceptible to PK
digestion (lanes 5 and 6).
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ucts) was significantly lower for the G allele than for the
A allele of 11-HSD1 (A allele, 3.29  0.09 vs. G allele,
2.23  0.13; P  0.05).
The A allele of SNP rs13306421 is present at less
than 1% in a southern European population of
women with and without PCOS
The 600 women genotyped (300 PCOS and 300 con-
trols comparable for age and body weight) were found to
be homozygous for the G allele at rs13306421. Accord-
ingly, the frequency of theA allele is considerably less than
1% in this population.
Discussion
We find no functional consequences of allelic variation at
rs846910, located in the 5 flanking region of the P2 pro-
moter ofHSD11B1 in a context where it could alter pro-
moter activity. Thus, despite its association with meta-
bolic phenotype (16–18), this polymorphism does not
appear to directly influence 11-HSD1 expression, al-
though it remains possible that it modifies response to
stimuli not tested here, for example, TNF. The lack of
effect on promoter activity is consistent with our recent
data showing no independent association of rs846910
withmetabolic phenotype in the same Southern European
population of women as examined here (Gambineri, A.,
Tomassoni, F.,Munarini, A., Stimson, R. H., Pagotto, U.,
Mioni, R., Chapman, K. E., Andrew, R., Pasquali, R. and
B. R. Walker, submitted for publication). SNP rs846910
is unlikely to affect the potential binding site of a tran-
scription factor because no sites formammalian transcrip-
tion factors were predicted in this region (using the Ali-
Baba2 program, which uses binding sites in TRANSFAC;
www.gene-regulation.com). Moreover, rs846910 lies
outside of the region that is highly conserved between
human and mouse, so is unlikely to be in an important
conserved regulatory region, although it may exert hu-
man-specific regulation. However, it may be in linkage
disequilibrium with another, functional, polymorphism
that accounts for the association with metabolic pheno-
type.Alternatively, the effect of the polymorphismonpro-
moter activity may have been too small to detect in the
current study but might become apparent in combination
with other functional polymorphisms. Indeed, in our re-
cent study, the combination of less common alleles at both
rs846910 and at rs12086634, a polymorphismpreviously
shown to influence transcription (19),was associatedwith
more prevalent metabolic syndrome and higher adipose
11-HSD1 activity (Gambineri, A., F. Tomassoni, A.
Munarini, R. H. Stimson, U. Pagotto, R. Mioni, K. E.
Chapman, R. Andrew, R. Pasquali, and B. R. Walker,
submitted for publication).
The reported polymorphism rs13306421, close to the
translation start of 11-HSD1, modulates translation of
the enzyme, with the A allele resulting in greater enzyme
expression in transfected cells and in in vitro translation
reactions,with ahigher ratioof full-length enzyme to trun-
cated products synthesized in vitro. The G allele results in
less full-length 11-HSD1 translated in vitro, but more of
the truncatedproducts. The latter finding suggests that the
A allele increases translation initiation at the ATG initia-
tor codon, concomitantly decreasing “leaky scanning”
where translation initiates at nearby internal AUG codons
rather than the AUG translation start codon (22). The N
terminus of 11-HSD1 is required for its insertion into the
endoplasmic reticulummembrane (31), and N-terminally
truncated 11-HSD1 is enzymatically inactive (33, 34).
Accordingly, the truncated products of leaky scanning are
predicted to be enzymatically inactive. The context of the
initiator AUG dictates the extent to which leaky scanning
occurs (22). The translation start of 11-HSD1 is both in
a suboptimal context (deviating from the consensus se-
quence at all three of the critical nucleotides immediately
preceding the start codon) and has several nearby AUG
codons (Met4, Met16, andMet31, being the closest). Ac-
cording to the Kozak rules (21), translation initiation is
sensitive to the bp at 2 when the 3 nucleotide is a
pyrimidine (as in HSD11B1) rather than the optimal pu-
FIG. 5. The A allele of rs13306421 generates a greater proportion of
full-length 11-HSD1 in vitro. Panel A, Representative autoradiograph
showing 35S-labeled products of in vitro transcription-translation of
11-HSD1 carried out with three independent preparations of each of
the A and G allele of rs13306421 (indicated above the lanes; G1–G3
and A1–A3). An arrowhead indicates full-length 11-HSD1, and the
arrow indicates the largest of the truncated products. Panels B and C,
Quantification by phosphorimager showing more full-length
nonglycosylated 11-HSD1 produced from the A allele (white bars)
than the G allele (black bars) of rs13306421 (B), but less of the largest
truncated product from the A allele (C). Levels of the two smaller
truncated products did not differ significantly between the A and G
alleles. Data are means  SEM (n  3) and are expressed relative to the
normal G allele, arbitrarily set to 100%. Significance was tested with
unpaired Student’s t test; *, P  0.05, **, P  0.01.
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rine. Thus, the A allele of rs13306421 may favor transla-
tion initiation at Met1, concomitantly decreasing initia-
tion from downstream AUGs. Only the fully glycosylated
full-length protein was detected in transfected cells. It is
likely that any truncated proteins would be subject to
rapid degradation.
Whether the polymorphism rs13306421 is truly a poly-
morphismormaymore properly be called amutation is an
openquestion.We failed to find a single case of theAallele
in our screen of 600 subjects. It is therefore highly unlikely
that this allele contributes to the alterations in 11-HSD1
activity associated with obesity and diabetes. Further-
more, although the A allele was reported at 0.5–1% in the
original African American and Japanese populations
(http://www.jmdbase.jp/snpinfo.asp?targetkeyimcj-snp&
keywordJMDBase000702), in a further study, geno-
typing of a total of 210 individuals in four different pop-
ulations (Nigeria, Japan, China, and Europe) detected
only the G allele (HapMap database). Thus, further stud-
ies in other populations are required to confirm whether
the A allele is indeed a polymorphism. Nevertheless, our
studies show the clear potential to influence levels of active
11-HSD1.
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